Facts
The Swedish research company Intervacc where Nordvacc is the majority owner, is on track to develop a vaccine, Strangvac® against strangles. Strangvac® has shown good documented protective effect against a disease that has lacked an adequate vaccine protection.
Read more about strangles and the research at Intervacc.